Zero Health levelEstablished women startup of medical devices, which goals to break the latest ground by developing a device for continuous monitoring of hormones, closed overwriting price $ 6.9 million in the financial round before the seed, although it is only just over a 12 months. The startup wants to get rid of the needs of invasive blood drawings and supporting tests that can lead to latest methods of treating conditions related to hormonal imbalance, and even latest innovations in the field of healthcare, similar to individual dosage of contraception based on hormone.
“One of our investors told us that there are companies that build fundamental technologies and there are companies that build packages around this technology; You are creating a new technology here, “says co -founder and general director of Ula Rustamov, discussing the development of the company, since we recently checked in with them last autumn, when they presented themselves on stage in TechCrunch Disrupt as a part of the Startup Battlefield competition.
“The goal is to create from this new market, right? In the same way CGMS [continuous glucose monitors] He did. Literally, out of nothing, they created a market worth many billions of dollars, “he contradicts. “This is by definition a completely new category of products – which, I hope, will inspire people to use the device and data to create many companies in addition and have a wave effect in the next few decades.”
Step by step
Building a completely latest product category of each belt can take some time. Entering that it is a hardware startup and a medical device to run, clear levels of zero health won’t find a way to support the paradigm change in the monitoring of hormones overnight.
That is why the team is also working on a one-man product with a disposable stone (pictured above in a prototype form), which they hope to be removed to use on prescription next year-to support intermittent hormonal tests related to medical use, similar to fertility (fertility (fertility ( fertility (IVF) and low testosterone (TRT).
The current prototype wearing incorporates small needles that allow you to take samples slightly below the skin to detect trace amounts of hormones.
This is a step towards monitoring the hormone, which ultimately hope to launch – pre -planned for 2028 – which is able to pull a constant measure of things like progesterone, estrogen and testosterone from the interstitial fluid of the user. (That is, a fluid that fills the spaces around the cells, acting as an intermediary between blood plasma and cells – because why biochemical compounds in the blood can even be detected in interstitial fluid.)
A continuous device for monitoring hormones – or moderately the data it downloads – can play a transformational role in increasing the scientific understanding of roles hormones in human biology – like CGM, they have transformed diabetes management (and greater than).
But the Zero Health level also builds a company-at the starting of the B2B company, aimed at selling technology in the network of healthcare suppliers-thanks to which the founders are working on tons of development of double products to shorten time to markets and fill the gap between the Big Bang Mission mission and what is now That’s possible.
“We think that we have a source of truths we can use for – i.e. interstitial fluid,” says Rustamova Techcrunch. “We think that there is an immediate, short -term product that we must always first start.
“The point is that it is continuous [hormone monitoring] … is a holy grail – this is the future – because it makes sense, in a sense, because it is without friction again, you can put it on and you can get really coherent measurements. But we also understand that today we must enter the market in a way that we would not try to change the protocol-and they did not have a seven-year research question “Let’s try to interpret this data”-so our first device is actually similar to fingerprints, but it is also a patch . “
Prototypical wearing is able to take measurements during the day when worn-by-reserving a series of information points in order to “immediately deliver values” for cases of use, similar to IVF, in which a woman could have many blood draws to monitor hormone levels.
Rustamova claims that the team hopes to finish clinical trials and secure the overturned one-off monitoring patch next year-with the eyes of approval from each the American regulator, FDA and the designation CE to enable them to sell European health care for them (says that he says that he says that They are undecided what could also be the first).
“I hope that this 12 months we would like to show a certain level of correlation [between levels of hormones the wearable patch can detect and levels detected via a blood draw] “This is a promise that I want to provide with previously seeded money,” he adds.
CTO and co -founder, Irene Jia, tells us that the team’s goal is to show a correlation of 90%+ with what their patch can raise compared to measuring hormone levels by taking blood.
Risk vs. prize
Although later-when we discuss the delay between blood-based readings and detection via interstitial fluid-rustamova they call to emphasize the difference in medical risk between CGM and hormone monitoring. It indicates that the risk of a person with diabetes (i.e. if blood glucose readings are delayed or disabled) can be extremely high, while hormone monitoring is normally not so high.
“In the case of glucose, you have potential fatal consequences of issuing improper reading or delay … [but when it comes to hormone monitoring] The risk of slight deviation or type of correlation is not so tight, “he tells us. “Of course, we will try to correlate as much as possible – but … there is a very different risk profile here.” She also noticed that the first CGM on the market had a lower correlation with blood reading than these devices.
It is suggested that the team’s goal is to continually lift the bar with accuracy. What – perhaps – suggestions on the reason why investors willingly put on the early round of this startup Medtech – with potential vs. Risks are distorted in a positive direction.
The second – undoubtedly – helpful factor is that the zero zero level does not focus only on women’s health problems; Monitoring men’s hormones is the basic element of the initial marketing strategy. (And it stays that almost all technical investors are still men who arrange plants to solve problems that talk about their interests).
The financing round before the sown level zero level was run by the European VC, Redalpine. HAX (SOSV), first entrepreneur (EF), and industry experts also contributed to the round – and SOSV had previously accepted the startup to his DeepTech/Hardware Hax Accelerator program, and Rustamova is also an EF graduate.
Commenting in a statement, Philip Kneis, an investor in Redalpine and a member of the board of Zero Zero, said: “We did it for blood pressure and we will do it again for hormones. Continuous hormonal measurement is one of the saints Diagnostics Grale, and as a fundamental scientific transition to engineering we could not be more excited about the zero level of health of the zero level in their mission of transforming hormone tracking with their innovative bio -bio -bio -bio – paving the way for a new era of personalized health management. “